Elixinol Global Competitors

Elixinol Global (OTCMKTS:ELLXF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for Elixinol Global and Abacus Health Products, as reported by MarketBeat.

Earnings & Valuation

This table compares Elixinol Global and Abacus Health Products' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Elixinol Global and Abacus Health Products' net margins, return on equity and return on assets.

Elixinol Global (OTCMKTS:ELLXF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.

Valuation and Earnings

This table compares Elixinol Global and Acreage's top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Elixinol Global and Acreage, as provided by MarketBeat.com.

Acreage has a consensus price target of $8.4333, indicating a potential upside of 204.45%. Given Acreage's higher possible upside, analysts clearly believe Acreage is more favorable than Elixinol Global.

Profitability

This table compares Elixinol Global and Acreage's net margins, return on equity and return on assets.

Summary

Acreage beats Elixinol Global on 2 of the 2 factors compared between the two stocks.

Elixinol Global (OTCMKTS:ELLXF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Elixinol Global and Applied Biosciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Elixinol Global and Applied Biosciences' revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Elixinol Global and Applied Biosciences, as provided by MarketBeat.

Elixinol Global (OTCMKTS:ELLXF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares Elixinol Global and Ayr Strategies' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Elixinol Global and Ayr Strategies' top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Elixinol Global and Ayr Strategies, as reported by MarketBeat.

Ayr Strategies has a consensus target price of $34.8571, suggesting a potential upside of 63.96%. Given Ayr Strategies' higher possible upside, analysts clearly believe Ayr Strategies is more favorable than Elixinol Global.

Summary

Ayr Strategies beats Elixinol Global on 2 of the 2 factors compared between the two stocks.

Elixinol Global (OTCMKTS:ELLXF) and Can B (NASDAQ:CANB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Elixinol Global and Can B, as provided by MarketBeat.

Profitability

This table compares Elixinol Global and Can B's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Elixinol Global and Can B's gross revenue, earnings per share (EPS) and valuation.

Elixinol Global (OTCMKTS:ELLXF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Profitability

This table compares Elixinol Global and Cansortium's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Elixinol Global and Cansortium's top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent ratings and price targets for Elixinol Global and Cansortium, as provided by MarketBeat.

Cansortium has a consensus target price of $1.20, suggesting a potential upside of 11.11%. Given Cansortium's higher possible upside, analysts plainly believe Cansortium is more favorable than Elixinol Global.

Summary

Cansortium beats Elixinol Global on 2 of the 2 factors compared between the two stocks.